XML 50 R29.htm IDEA: XBRL DOCUMENT v3.22.1

SEGMENT INFORMATION (Tables)

3 Months Ended

Mar. 31, 2022

Segment Reporting [Abstract]

Schedule of Information about Reportable Segments and Reconciliation of Segment Net Sales and Pre-Tax Income

The table below presents information about Edwards Lifesciences' reportable segments (in millions):

									Three Months Ended March 31,
															2022						2021
Segment Net Sales
United States															$	749.5					$	674.7
Europe															300.1						255.4
Japan															140.9						127.7
Rest of World															142.3						124.5
Total segment net sales															$	1,332.8					$	1,182.3
Segment Operating Income
United States															$	511.5					$	466.1
Europe															166.6						133.3
Japan															99.5						87.6
Rest of World															59.7						47.3
Total segment operating income															$	837.3					$	734.3

The table below presents reconciliations of segment net sales to consolidated net sales and segment operating income to consolidated pre-tax income (in millions):

									Three Months Ended March 31,
															2022						2021
Net Sales Reconciliation
Segment net sales															$	1,332.8					$	1,182.3
Foreign currency															8.4						34.3
Consolidated net sales															$	1,341.2					$	1,216.6
Pre-tax Income Reconciliation
Segment operating income															$	837.3					$	734.3
Unallocated amounts:
Corporate items															(419.4)						(357.7)
Intellectual property litigation expenses, net															(7.1)						(6.4)
Change in fair value of contingent consideration liabilities															2.9						4.5
Foreign currency															25.1						8.8
Consolidated operating income															438.8						383.5
Non-operating (expense) income															(2.7)						5.8
Consolidated pre-tax income															$	436.1					$	389.3

Schedule of Enterprise-Wide Information

The following enterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated condensed financial statements.

									Three Months Ended March 31,
															2022						2021
Net Sales by Geographic Area
United States															$	749.5					$	674.7
Europe															311.1						280.0
Japan															135.5						132.3
Rest of World															145.1						129.6
															$	1,341.2					$	1,216.6
Net Sales by Major Product Area
Transcatheter Aortic Valve Replacement															$	881.3					$	791.7
Transcatheter Mitral and Tricuspid Therapies															27.0						16.3
Surgical Structural Heart															220.8						213.0
Critical Care															212.1						195.6
															$	1,341.2					$	1,216.6

X

- Definition

Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

+ Details

Name:	us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration